This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
All content for Centeno-Schultz Clinic - Podcasts is the property of Centeno-Schultz Clinic Staff and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
What is a Clivoaxial Angle? Why is It Important in CCI or ME/CFS?
Centeno-Schultz Clinic - Podcasts
1 hour 2 minutes
1 month ago
What is a Clivoaxial Angle? Why is It Important in CCI or ME/CFS?
Dr. Centeno reviews the CXA measurement and the fact that it's a dynamic concept and what numbers are concerning, and which CXAs are probably not important. https://youtube.com/live/Hr4UoHDBfgk
Centeno-Schultz Clinic - Podcasts
This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
